1. Fleish H. Bisphosphonates in bone diseases. From the laboratory to the patient.

Third Edition. The Parthenon Publishing Group Inc. London, 1997

2. Kanis JA. Drugs used for the treatment of Paget´s disease of bone. London:

Martin Dunnitz,1991:139-216.

3. O´Doherty DP, Bickerstaff DR, McCloskey EV, et al. Treatment of Paget´s disease of bone with aminohydroxybutylidene-1bisphosphonate. J Bone Min

Res 1990:5, 483-491.

4. Adami S, Salvagno, Guarrera G, et al. Treatment of Paget´s disease of bone with intravenous 4 amino-1hydroxybutylidene-1,1bisphosphonates. Calcif

Tissue Int 1986;39:226-229.

5. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget´s disease of bone. J Clin Endocrinol Metabol 1996;81 (3):961-967.

6. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical ad radiologic improvement in Paget´s disease of bone treated with alendronate. A randomized, placebo-controlled trial. Am J Med 1996;101:341-348.

7. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget´s disease of bone. Bone 1994;15:415-417.

8. Miller PD, Brown SP, Siris ES, et al. A randomized, double blind comparision of risendronate and etidronate in the treatment of Paget´s disease of bone.

Am J Med 1999;106:513-520.

9. Siris E, Chines A, Altman R, et al. Risendronate in the treatment of Paget´s disease of bone: an open label, multicenter study. J Bone Min Res 1998;13:1032-1038.

10. Bickerstaff DR, O´Doherty DP, McCloskey EV, et al. Effects of amino-butylidene diphosphonate in hypercalcemic due to malignancy. Bone 1991;12:17-20.

11. Ling PJ, A´Hern RP, Hardy JR, et al. An analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 1995;72 (1):206-209.

12. Rizzoli R, Thiebaud D, Bundred N, et al. Serum parathyroid hormone-related protein levels ad response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocinol Metab 1999; 84 (10): 3545-3550.

13. Fleish H. Bisphosphonates: pharmacology and use in the treatment ofhypercalcemic ad metastatic bone disease. Drugs 1991;42:919-944

14. Benson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients in patients with advanced multiple myeloma. N Engl J Med 1996; 334 (8): 488-493.

15. Mayo PP, Lipton A, Berenson J, Hortobagyi G.Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 2000; 88(1): 6-14.

16. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology Guideline on the Role of Pbisphosphonate in Breast Cancer. J Clin Oncol 2000;18 (6):1378-1391.